Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB-0895 in mild to moderate asthma and COPD
NCT07116889Phase 1Active, not recruiting
- Sponsor
- Generate Biomedicines
- Start
- Dec 2023
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of GB-0895 in asthma and chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Generate Biomedicines. Primary endpoint: Treatment-Emergent Adverse Events. Started Dec 2023; status: active, not recruiting.
02
Drugs
GB-0895
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07116889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116889.